Dashboard
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 6.70%
- Poor long term growth as Operating profit has grown by an annual rate of 24.32%
With a growth in Net Profit of 149.22%, the company declared Very Positive results in Jun 25
With ROE of 25.77%, it has a very attractive valuation with a 2.87 Price to Book Value
High Institutional Holdings at 48.77%
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
Kingstone Cos., Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is Kingstone Cos., Inc. overvalued or undervalued?
As of 21 November 2025, the valuation grade for Kingstone Cos., Inc. has moved from attractive to fair. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 11, a Price to Book Value of 2.87, and an EV to Sales ratio of 1.25. In comparison to peers, Crawford & Co. has a higher P/E of 17.88, while GoHealth, Inc. shows a significantly lower P/E of 2.12, indicating that Kingstone is positioned between these two companies in terms of valuation. While Kingstone has experienced a remarkable 3-year return of 1520.70%, it has underperformed relative to the S&P 500 over the past year, with a return of -2.64% compared to the index's 11.00%. This suggests that although the company has had strong historical performance, its current valuation does not reflect the same growth potential moving forward....
Read MoreIs Kingstone Cos., Inc. overvalued or undervalued?
As of 21 November 2025, the valuation grade for Kingstone Cos., Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 11, a Price to Book Value of 2.87, and an EV to Sales ratio of 1.25. In comparison, peer Crawford & Co. has a higher P/E ratio of 17.88, while GoHealth, Inc. shows a significantly lower P/E of 2.12, highlighting the varying valuations within the industry. Despite the recent downgrade in valuation, Kingstone's stock has outperformed the S&P 500 over the last three years, with a remarkable return of 1483.87% compared to the S&P 500's 67.17%. However, the year-to-date performance shows a decline of 3.03% against the S&P 500's gain of 12.26%, suggesting that while the long-term outlook has been strong, recent performance may warrant caution....
Read MoreIs Kingstone Cos., Inc. overvalued or undervalued?
As of 14 November 2025, the valuation grade for Kingstone Cos., Inc. has moved from attractive to fair. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 11, a price to book value of 2.87, and an EV to EBITDA of 76.30. In comparison to peers, Crawford & Co. has a higher P/E ratio of 17.88, while GoHealth, Inc. shows a significantly lower P/E of 2.12, indicating that Kingstone is positioned in the middle of its peer group. Despite the fair valuation, Kingstone's recent performance against the S&P 500 is not available for analysis, which limits the ability to draw conclusions about its relative market performance. Overall, the current valuation suggests that Kingstone Cos., Inc. is neither undervalued nor overvalued, aligning closely with its peers in the capital markets industry....
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 8 Schemes (8.1%)
Held by 23 Foreign Institutions (6.12%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 151.11% vs 1,000.00% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
YoY Growth in year ended Dec 2024 is 396.77% vs 72.44% in Dec 2023






